Warren K G, Catz I
Department of Medicine (Neurology), University of Alberta, Edmonton, Canada.
J Neurol Sci. 1995 Nov;133(1-2):85-94. doi: 10.1016/0022-510x(95)00187-7.
A double blind Phase 1 clinical research project was conducted in vivo in multiple sclerosis (MS) patients to determine the effect of myelin basic protein (MBP) synthetic peptides on free (F) and bound (B) titers of anti-MBP in cerebrospinal fluid (CSF). Intrathecal administration of peptide MBP75-95, either as a single dose, or as repeated injections for periods up to 10 weeks, produced complete binding-neutralization of F anti-MBP with no change in B levels. A control peptide MBP35-58 had no effect on F and B anti-MBP levels. Intravenous administration of MBP75-95 resulted in significant decline of F and B CSF anti-MBP levels over a period of one month. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP was further localized to an area between Pro85 and Pro96.
开展了一项双盲1期临床研究项目，在体内对多发性硬化症（MS）患者进行研究，以确定髓鞘碱性蛋白（MBP）合成肽对脑脊液（CSF）中抗MBP游离（F）滴度和结合（B）滴度的影响。鞘内注射肽MBP75 - 95，无论是单次给药，还是重复注射长达10周，均可使F抗MBP完全结合中和，而B水平无变化。对照肽MBP35 - 58对F和B抗MBP水平无影响。静脉注射MBP75 - 95导致在一个月内F和B脑脊液抗MBP水平显著下降。对MS患者鞘内或静脉注射MBP合成肽均未产生任何不良神经学影响，也未出现全身并发症。MS抗MBP的MBP表位进一步定位于Pro85和Pro96之间的区域。
